Canagliflozin
Approved · FDA / EMAAlso known as Invokamet, Invokana, Canagliflozina.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: CANAGLIFLOZIN (NDA204042)
Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease
Indication expansion: CANAGLIFLOZIN (NDA204042)
Label change: CANAGLIFLOZIN (NDA204042)
Label change: CANAGLIFLOZIN (NDA204042)
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
Confidence is high because multiple independent trials consistently report HbA1c, with a narrow uncertainty band; publication incorporation remains limited.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Invokana is indicated for the treatment of adults and children aged 10 years and older with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and… Show full indicationShow less
Invokana is indicated for the treatment of adults and children aged 10 years and older with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Nanjing Medical University, Nanjing First Hospital
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Diabetes, obesity & metabolism2
- Cardiovascular diabetology1
- Circulation1
- Journal of diabetes investigation1
- Gouda M2
- Iijima H2
- Inagaki N2
- Kadowaki T2
- Kaneko G2
- Kondo K2
- Maruyama N2
- Nakanishi N2
- Graduate School of Medicine2
- Brigham and Women's Hospital1
- Department of Clinical Pharmacy and Pharmacology1
- Department of Nephrology and Laboratory Medicine1
- Imperial College London1
- Indiana University School of Medicine and VA Medical Center1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.